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Abstract 
Background: Authors and colleagues have continued clinical research for hemodialysis patients. Currently, a pilot study presents intervention of 
carnitine for changes of the body composition.  
Subjects and Methods: Subjects were six patients on hemodialysis with intervention of carnitine (group 1). Average data were 74.3 years, 65.4  
kg, 22.6 in BMI. As levocarnitine, L-Cartin FF injection 1000 mg was administered three times a week for six months. Group 2 has six control 
patients for age-, sex-, body weight, BMI-matched (group 2). Body composition of muscle and fat tissues were measured by InBody 770 on 0 and 
6 months.  
Results: In group 1, muscle volume and skeletal muscle showed increasing tendency without statistical significance. In contrast, there were 
significant decreases of body fat volume (22.3 kg vs 20.5 kg, 39.0% vs 35.8%) (p<0.05). No significant differences were found in hemoglobin, 
total protein, albumin and Cardio-Thoracic Ratio (CTR) of chest X-ray. Group 2 showed no significant changes.  
Discussion and Conclusion: Hemodialysis patients often have muscular reduction. Previous reports showed improved lean body mass by 
carnitine administration, which may support our result. These results from current pilot study would be expected to become useful reference data 
in the pathophysiological investigation in patients on hemodialysis. 
Keywords: Chronic kidney disease, Endogenous erythropoietin, Erythropoiesis stimulating agent, Carnitine, Cardio renal anemia syndrome.
Abbreviations: CKD-Chronic Kidney Disease, EPO-Endogenous Erythropoietin, ESA-Erythropoiesis Stimulating Agent, CTR-Cardio-Thoracic 
Ratio, TCA-Tricarboxylic Acid, FC- Free-Carnitine, AC-Acyl-Carnitine, HD-Hemodialysis, BMI-Body Mass Index, ECW-Extracellular Water, 
TBW-Total Body Water, GCP-Good Clinical Practice, CRF-Chronic Renal Failure, HRQL-Health-Related Quality of Life, NCV-Nerve 





In recent years, diabetes and Chronic Kidney Disease (CKD) have been 
increased worldwide and become crucial problems from medical, 
social and economic points of view. As clinical condition of these 
patients aggravates, their renal anemia status reveals exacerbation. 
These causes include decreased production of the Endogenous 
Erythropoietin (EPO), which is accompanied with decreasing renal 
function [1].  
 
Furthermore, the life of the red blood cell shortens from impaired renal 
function or uremia. Then, this process may decrease the reactivity of 
EPO for hematopoietic cell. When renal anemia is left untreated, CKD 
will be aggravated. Then, it will lead to the end-stage renal failure and 
cardiovascular disease associated with CKD more frequently [2]. 
Therefore, treatment with Erythropoiesis Stimulating Agent (ESA) has 
been recommended for renal anemia. ESA has also been used for 
patients with end-stage renal failure in the actual clinical practice. 
 
 
On the other hand, carnitine has been an important factor in 
hemodialysis treatment. L-carnitine is a water-soluble amine, which 
has been present in the mitochondria of the tissues of cardiac muscle, 
skeletal muscle, brain, liver and so on. It exists as Free-Carnitine (FC) 
or Acyl-Carnitine (AC). Carnitine shows high dialyzability and is often 
deficient in patients with hemodialysis. The reason is that those 
patients are undernourished due to inflammatory condition.  
 
Energy may be produced by beta-oxidation or through the 
Tricarboxylic Acid (TCA) cycle. It is by conveying long-chain fatty 
acids through the inner mitochondrial membrane to carnitine [3]. 
Carnitine deficiency has been known in patients on Hemodialysis 
(HD). It has been reported that administration of carnitine may bring 
clinical effects, such as improving cardiac function, decreasing muscle 
symptoms with muscle spasm and increasing the response of EPO to 
anemia [4].  
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Furthermore, there are other beneficial effects, including facilitation of 
decrease in hypotension during dialysis, cardiomegaly, increasing the 
red blood cell lifespan, improvement of erythrocyte membrane fat 
metabolism and improving the nutritional status. Our medical group 
has been involved in dialysis treatment for many patients with chronic 
renal failure for years. We have continued some research studies 
concerning patients on hemodialysis [5-7]. We have conducted a study 
that combined the above-mentioned situations. As a pilot study, 
carnitine was administered under the conventional treatment associated 
with fundamental ESA treatment. For the protocol, we examined the 
changes in muscle mass/proportion and fat mass/proportion. In this 
article, these data are shown and discussed in comparison with similar 





Subjects in this study were six patients with CRF undergoing 
hemodialysis three times a week. They included one male and five 
females, aged 68-86 with an average of 74.3 years old. The average 
body weight was 65.4 kg and the average BMI was 22.6 kg/m2. There 
were two groups in this study. Group 1 is an intervention group, in 
which 6 subjects were administered carnitine for 6 months. Group 2 is 
a control group, in which 6 subjects were not given carnitine. As to the 
control group, 6 subjects were selected as age-, sex-, body weight-, 
Body Mass Index (BMI)-matched in comparison with those of 6 
subjects of an intervention group.  
 
Methods 
The main research purpose was the measurement the body 
composition. It included the data of muscle mass and proportion and 
fat mass and proportion. These data were analyzed by InBody 770 
(CryoUSA) [10]. The measurements were done 0 and 6 months along 
the schedule of the intervention of carnitine. 
 
Body Composition 
Analysis of the body composition was conducted by using InBody 770 
[10]. It can measure not only fat tissue, but also the amount of muscle 
tissue and distribution of body water [11]. It can be checked by using 
compliment Cryoskin, red light therapy and other tools. As a useful 
apparatus in the clinical practice, the InBody 77 can store and track the 
data including total body composition analysis, muscle-fat analysis, 
obesity analysis, segmental lean analysis, Extracellular Water/Total 




These patients have been on regular hemodialysis for years. In detail, 
they have i) regular HD treatment three times a week, ii) regular ESA 
treatment twice a month. In this study, there are two groups, which are 
intervention group and control group. In the former group, regular 
carnitine was administered three times a week just after each 
hemodialysis. The study protocol includes the administration for 6 
months. Several data of biomarkers were measured and compared at 
two points, which were before and after the intervention. The data are 
shown in 0 and 6 months in Table 1 and Table 2. This report included 
six HD patients with the intervention of carnitine administration. The 
ordinary protocol has two groups with and without the intervention, but 
this report would be the pilot study of carnitine administration. 
Consequently, there is one group of HD patients that are investigated 
for the measurement of muscle and fat at 0 and 6 months along the 
schedule of the intervention of carnitine. 
 
Medical agents 
The administered medical agents involved in this study are ESA and 
carnitine. As the treatment of ESA, Darbepoetin Alfa (Genetical 
Recombination) was provided to the patients with Chronic Renal 
Failure (CRF).  
 
Patients were provided Darbepoetin Alfa injection syringe (40 or 60 
microgram). It is recognized as anti-anemic, erythropoietin receptor 
agonist, and for anemia due to CKD with B03 X A02 for ATC code 
and pharmaceutical classification No. 3999 [12]. Darbepoetin alfa was 
proved to be beneficial for adult and also pediatric patients [12]. The 
reasons are from similar pharmacokinetics, greater maximum dose and 
less injection frequency in comparison with that of recombinant human 
erythropoietin. Carnitine was administered by L-Cartin FF injection 
1000mg to patients three times a week in an average with 
Levocarnitine, which is (R)-3-Hydroxy-4-trimethylammoniobutanoate 
[13]. It was registered as 22400AMX01482, which has been provided 
for the treatment for carnitine deficiency [4].  
 
 
Group 1 (carnitine) Group 2 (control) 





74.3 ± 2.7 75.3 ± 2.7 
 




56.4 ± 4.9 56.1 ± 5.5 np 56.2 ± 4.9 56.0 ± 5.0 np 
BMI 
(kg/m2) 





32.1 ± 2.7 33.6 ± 3.0 np 32.9 ± 3.2 32.5 ± 2.9 np 
Skeletal 
muscle (kg) 
17.7 ± 1.7 18.3 ± 1.9 np 18.7 ± 2.0 18.3 ± 1.9 np 
Skeletal 
muscle (%) 





22.3 ± 3.0 20.5 ± 3.3 * 20.9 ± 3.2 21.3 ± 3.4 np 
Body Fat 
(%) 
39.0 ± 3.3 35.8 ± 3.6 * 36.9 ± 4.4 37.7 ± 4.6 np 
Note: Data represent the mean value and standard error of the mean (SEM), Intervention is the 
adminstration of Carnitine injection for six months, dif: difference between 0 mont and 6 
month, *: significant difference between 0 month and 6 month (p<0.05), np: not significant 
between 0 month and 6 month. 





Group 1 (carnitine) Group 2 (control) 
0 month 6 month dif 0 month 6 month dif 
Blood test 




6.7 ± 0.1 6.8 ± 0.1 np 6.9 ± 0.2 6.6 ± 0.1 np 
Albumin 
(g/dL) 
3.4 ± 0.1 3.3 ± 0.1 np 3.5 ± 0.2 3.3 ± 0.1 np 
Chest X-ray 
CTR (%) 52.9 ± 3.7 53.1 ± 3.4 np 53.3 ± 4.2 52.8 ± 3.6 np 
Note: Data represent the mean value and standard error of the mean (SEM), Intervention is the 
adminstration of Carnitine injection for twelve months, dif: difference of data between 0 month 
and 6 month, np: not significant difference between 0 month and 6 month. 
Table 2: Results of changes of biomarkers. 
 
Ethical Considerations 
This research study has been fundamentally conducted in compliance 
with the adequate ethical principles that were based on the Declaration 
of Helsinki. Furthermore, there was some commentary for the Ethical 
Guidelines for Research in the medical field for Human beings and in 
the conduction of the Good Clinical Practice (GCP). As to the 
protection of human rights, there were some ongoing considerations. 
Moreover, “Ethical Guidelines for Epidemiology Research” was 
adequately applied according to the related guideline. These principles 
were originated from Japan by the Ministry of Education, Culture, 
Sports, Science and Technology and also by the Ministry of Health, 
Labor and Welfare.  
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Regarding the current investigation about carnitine administration for 
hemodialysis patients, we have obtained the written informed consents 
from all of the subjects of carnitine group and control group. In 
addition, the ethical committee for the clinical research in Kanaiso 
Hospital was established. The committee included the president, the 
vice-president, and the director of the Pharmaceutical department, the 
head nurse of the nursing department, director of the administration 
department and experts in the medical and legal specialties. We have 
fully discussed the research content and made confirmation that this 





The main data of this study are shown in Table 1. In group 1 
(intervention group), average value in age, weight and BMI before 
intervention was 74.3 years old, 56.4 kg and 22.6, respectively. As for 
the changes of muscle between before and after the intervention of 
providing carnitine, muscle volume (kg), skeletal muscle (kg) and 
skeletal muscle (%) showed the increasing tendency. However, these 
were not statistically significant (p>0.05). There was significant 
decrease of body fat volume (22.3 kg vs 20.5 kg) and percentage 
(39.0% vs 35.8%) between before and after intervention (p<0.05). In 
group 2 (control group), the values of the age, weight and BMI were 
almost similar to those of group 1. There were not significant changes 
in those biomarkers, including muscle and fat tissues. The adventitious 
data of both groups between before and after intervention were shown 
in Table 2. There were not significant differences in hemoglobin, total 
protein, albumin and CTR of chest X-ray in both of the groups 




Authors and colleagues have continued pathophysiological research 
among hemodialysis, diabetes, Nerve Conduction Velocity (NCV) and 
so on. [6,7,14,15]. During our continuous clinical research, we have 
tried a pilot study this time, in which carnitine was administered to HD 
patients with the investigation of the changes in muscle 
mass/proportion and fat mass/proportion. There are several important 
matters to be discussed in this article. They include hemodialysis, 
chronic renal failure, ESA, carnitine and current research data, which 
are described in this order as follows. 
 
Firstly, the administration of ESA has become widespread for renal 
anemia in recent years. ESA is a peptide preparation with a structure 
similar to EPO produced in the kidney. It can act on erythroid 
progenitor cells in the bone marrow, promote differentiation and 
proliferation into red blood cells, and improve renal anemia.According 
to the ESA administration guideline; it is recommended that the Hb 
level of approximately 10-12 g/dL for dialysis patients and 
approximately 11-13 g/dL for CKD patients as a treatment target for 
ESA administration [16]. The guideline has been practically useful 
with high quality in 46 pages and 282 references. 
 
In our clinic of the authors, ESA has been administered to the 
hemodialysis patients according to this guideline. Furthermore, BUN, 
Cre, UA, Hb, TP and Alb were stable for half a year in six subjects and 
also in more than 90 other dialysis patients. However, current study 
showed no comparison between the six subjects and control subjects 
with the same age, sex, and renal failure severity. Conventionally, it 
has been said that end-stage renal failure has shown a vicious cycle 
interacting cardiac function, renal function, and anemia each other. 
These factors may be independent risk factors for ESA efficacy on 
dialysis [17]. Consequently, these three factors have been proposed to 
present the concept of Cardio-Renal-Anemia Syndrome [18,19]. 
Treatment of renal anemia with ESA has revealed to improve memory, 
motivation and quality of life, reduce hospitalization risk, and 
contribute to improving the prognosis of dialysis patients [19,20]. On 
the other hand, there was an opposite report. As for the treatment of 
anemia from CRF, there was a study of effect of ESAs for Health-
Related Quality Of Life (HRQOL). They were analyzed from 17 
systematic review and meta-analyses. They have used Short Form-36 
Health Survey (SF-36), Kidney Dialysis Questionnaire (KDQ) and 
others. The results showed that ESA therapy for higher hemoglobin 
targets did not have important differences of HRQOL in patients with 
CRF [21].  
 
Secondly, L-carnitine has been one of the water-soluble amines, which 
molecular weight is 162 [3]. It is present in the mitochondria of several 
tissues, such as skeletal muscle, cardiac muscle, brain, liver and so on, 
as the molecular states of Acyl-Carnitine (AC) or Free-Carnitine (FC) 
[3]. Carnitine shows higher dialyzability and has been said to be often 
in deficiency in hemodialysis patients. It may be due to the mal-
nourished condition of these patients from persistent inflammation. 
Hemodialysis patients have various clinical symptoms depending on 
the specific condition. They may include multiple factors, such as 
muscular symptoms (swelling, weakness, extreme malaise), cardiac 
symptoms (cardiac hypertrophy, cardiomyopathy, cardiac dysfunction, 
arrhythmia, hypotension during dialysis, sudden death, etc.), 
erythropoietin-resistant anemia. In such cases, pathophysiological 
involvement of carnitine deficiency has been strongly suspected [22]. 
These symptoms are called dialysis-related carnitine deficiency or 
Dialysis-Related Carnitine Disorder (DCD). There have already been 
reports of carnitine homeostasis and replacement therapy in dialysis 
patients [23]. 
 
Thirdly, we have conducted a pilot study of carnitine administration for 
patients with hemodialysis. As a result, the body composition showed 
that the muscle mass and proportion tended to increase slightly, and the 
fat mass and proportion significantly decreased. These changes may be 
involved in carnitine administration. However, from statistic point of 
view, the control group would be necessary to evaluated the possible 
effect of carnitine. In the current protocol, we applied several patients 
to give the intervention. In the next research schedule, we would plan 
to set several groups in order to compare the detail data. 
 
There are some previous reports which can become reference research. 
The Lean Body Mass (LBM) by carnitine administration for 12 months 
was investigated by Maruyama, et al. [22]. They studied two groups 
(n=42, each), which were L-carnitine group and control group. LBM in 
the former did not change significantly, but decreased significantly in 
the latter. The difference in mean LBM between the groups was 2.92% 
(95% CI 1.28-4.61; P=0.0007). Furthermore, Arm Muscle Area 
(AMA) did not change significantly in the former, but decreased 
significantly in the latter. The difference in mean ABA between them 
was 6.22% (p=0.037) [8]. Consequently, L-carnitine supplementation 
seemed to be useful for preservation of muscle mass. There has been 
another report of L-carnitine supplementation for 6 months in 50 
hemodialysis patients for 6 months [9]. 
 
As a result, some biomarkers increased such as prealbumin, Fat Tissue 
Index (FTI), total cholesterol and LDL-C, while some biomarkers 
decreased such as Lean Tissue Index (LTI), LTI/FTI ratio and HDL-C. 
Thus, L-carnitine supplementation has brought an improvement of 
Malnutrition-Inflammation Score (MIS) to some extent [9]. From these 
previous reports, there would be various possibilities of the effects by 
the administration of L-carnitine. Further accumulation of investigation 
will be necessary. Regarding the influence for cardiac and pulmonary 
function, our current study has showed that there was no significant 
change in the CTR value by chest X-ray. The improvement of cardiac 
function was reported in the previous report by L-carnitine 
supplementation [24]. 
 
There are several limitations in current study as follows: 
 There are few cases,  
 Control group would be necessary to compare, 
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 Various differences are observed as to the hemodialysis 
situation, administration amount of medical agents and 
control of anemia, 
 Serum concentration of some biomarkers would be 
desirable to judge clinical efficacy.  
 
In summary, current article has showed the intervention of carnitine for 
hemodialysis patients associated with the possible effects on muscle 
and fat tissues. Authors expect that this pilot report would be useful 
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